Gland Pharma Limited

GLAND

INE068V01023

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 05:17:53 21/06/2024 pm IST			5-day change	1st Jan Change
1,816 ^INR	-0.81%		-1.62%	-5.64%

20/06	Fosun Pharma Trims Stake in Gland Pharma to 51.83%	MT
18/06	Fosun Pharma Industrial Reportedly to Pare 5% Stake in Gland Pharma for $172 Million	CI

Gland Pharma Limited Receives Approval from the United States Food and Drug Administration for Eribulin Mesylate Injection 0.5 Mg/ML Single Dose Vial

April 06, 2024 at 02:17 pm IST

Gland Pharma Limited (Gland or Company) has received approval from the United States Food and Drug Administration (USFDA) for Eribulin Mesylate Injection, 0.5 mg/mL Single Dose Vial (Product). The Product is expected to be the first generic approval on the market, and the Company expects to launch this product in the near term through its marketing partner. The Product has US sales of approximately USD 92 million for twelve months ending in February 2024, according to IQVIA.

The Company is co-developing several complex injectables, including this Product, with Orbicular Pharmaceutical Technologies Private Limited.

Latest news about Gland Pharma Limited

Fosun Pharma Trims Stake in Gland Pharma to 51.83%	20/06	MT
Fosun Pharma Industrial Reportedly to Pare 5% Stake in Gland Pharma for $172 Million	18/06	CI
Gland Pharma Limited Announces Management Changes	07/06	CI
Gland Pharma Limited Announces Resignation of C.S. Venkatesan as Sr. Vice President (R&D) and SMP, Effective June 30, 2024 and July 1, 2024 Respectively	31/05	CI
Gland Pharma Gets Zero Observations from US FDA for API Facility in Andhra Pradesh, India	24/05	MT
Jefferies Adjusts Gland Pharma's Price Target to INR2,240 From INR2,400, Keeps at Buy	23/05	MT
Gland Pharma Posts Surge in Fiscal Q4 Consolidated Net Profit	23/05	MT
Transcript : Gland Pharma Limited, Q4 2024 Earnings Call, May 22, 2024	22/05
Gland Pharma Limited Board Recommends Final Dividend for the Fiscal Year Ending March 31, 2024	22/05	CI
Gland Pharma Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	22/05	CI
Gland Pharma Limited Reports Earnings Results for the Full Year Ended March 31, 2024	22/05	CI
Gland Pharma Gets US FDA's Approval for Generic ALS Drug	07/05	MT
Gland Pharma Limited Receives Approval from the United States Food and Drug Administration for Edaravone Injection	07/05	CI
Gland Pharma Gets US FDA's Approval for Generic Stem Cell Mobilizer Injection	07/05	MT
Gland Pharma Limited Receives Approval from the United States Food and Drug Administration for Plerixafor Injection	07/05	CI
KKR to buy India's Healthium Medtech at $839 million valuation, sources say	06/05	RE
Gland Pharma Names COO	29/04	MT
Gland Pharma Limited Approves Appointment of Mr. Satnam Singh Loomba as Chief Operating Officer, Effective May 1 ,2024	29/04	CI
Gland Pharma Gets US FDA's Final Approval for Generic Drug for Luteinizing Hormone Surges	29/04	MT
Gland Pharma Receives Approval for Cetrorelix Acetate for Injection	29/04	CI
Nicomac Machinery and RP Advisory Services Reportedly Likely to Sell 4.4% Stake in Gland Pharma via Block Deals	08/04	CI
Gland Pharma Gets US FDA Approval for Eribulin Mesylate Injection	08/04	MT
Gland Pharma Limited Receives Approval from the United States Food and Drug Administration for Eribulin Mesylate Injection 0.5 Mg/ML Single Dose Vial	06/04	CI
Gland Pharma COO, Chief Technical Officer Step Down	25/03	MT
Gland Pharma Limited Announces Change in Management	25/03	CI

Chart Gland Pharma Limited

Duration

Period

More charts

Company Profile

Gland Pharma Limited is an India-based generic injectables manufacturer. The Company specializes in sterile injectables, oncology, and ophthalmic, with a specific focus on complex injectables, NCE-1s (New Chemical Entities), First-to-File products, and 505(b)(2) filings. The Company functions primarily on a business-to-business (B2B) model and has a record in pharmaceutical research and development, manufacturing, and marketing of complex injectables. The Company offers a range of delivery systems, including liquid vials, lyophilized vials, pre-filled syringes, ampoules, bags, and drops. It is also in the process of including new delivery systems such as pens and cartridges into its product portfolio. Its key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, Daptomycin Injection, among others. Its therapeutic products categories include Anti Malarials, Anti-Infectives, Anti-Neoplastics, Gynaecological, Hormones, and others.

Sector

Pharmaceuticals

Calendar

17/07/2024 - Q1 2025 Earnings Release (Projected)

Related indices

NIFTY 100

More about the company

Income Statement Evolution

More financial data

Ratings for Gland Pharma Limited

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

1,816 INR

Average target price

1,827 INR

Spread / Average Target

+0.62%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
GLAND PHARMA LIMITED	-5.64%	3.58B
ELI LILLY AND COMPANY	+51.63%	796B
NOVO NORDISK A/S	+41.51%	628B
JOHNSON & JOHNSON	-5.10%	358B
MERCK & CO., INC.	+19.90%	331B
ABBVIE INC.	+9.95%	301B
ASTRAZENECA PLC	+17.66%	244B
ROCHE HOLDING AG	+3.39%	228B
NOVARTIS AG	+10.75%	214B
AMGEN INC.	+6.99%	165B

Other Pharmaceuticals